WILMINGTON, North Carolina, January 2 /PRNewswire/ --
- Strengthens global leadership in drug development
PPD, Inc. (Nasdaq: PPDI) today announced the appointment of Sebastian Pacios, M.D., as senior vice president of clinical operations for Europe, Middle East and Africa (EMEA). In this role, Dr. Pacios will oversee Phase II-IV clinical development for PPD's operations in these geographic regions.
Dr. Pacios brings extensive clinical research experience in national and international settings. Prior to joining PPD, he co-founded and rapidly grew a regional contract research organization (CRO) prior to its acquisition three years later. He then held a number of senior management positions with a global CRO, most recently serving as vice president, responsible for clinical research and project management in Europe, Africa and Asia-Pacific.
"With his impressive global experience managing drug development across five continents, Sebastian Pacios will complement and strengthen our senior leadership team," said William Sharbaugh, chief operating officer of PPD. "EMEA has been and will continue to be a very large and important region for PPD clinical research operations, and we are pleased to have a leader of Sebastian's caliber join our team."
Dr. Pacios earned his medical degree from the Universidad Autonoma de Madrid and is a licensed practical physician at the Colegio de Medicos de Madrid. He has taught clinical trial management courses in Spain for a number of years at the University of Pamplona, the University of Barcelona, the University of Alcala de Henares and the University of Valencia. Dr. Pacios is affiliated with the Association of Clinical Research Professionals.
PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 30 countries and more than 10,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at http://www.ppdi.com.
Except for historical information, all of the statements, expectations and assumptions contained in this news release, including expectations and assumptions about the above-named employee's performance, are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: the ability to attract and retain key personnel; continued success in sales growth; loss of large contracts; increased cancellation rates; economic conditions and outsourcing trends in the pharmaceutical, biotechnology, medical device, academic and government industry segments; competition within the outsourcing industry; risks associated with and dependence on collaborative relationships; risks associated with the development and commercialization of drugs, including earnings dilution and obtaining regulatory approval; risks associated with acquisitions and investments, such as impairments; rapid technological advances that make our products and services less competitive; risks that we may not continue our dividend policy; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.
Contacts Media: Sue Ann Pentecost +1-919-456-5890 sueann.pentecost@rtp.ppdi.com Analysts/Investors: Craig Eastwood +1-910-558-7517 craig.eastwood@wilm.ppdi.com
Web site: http://www.ppdi.com
Media, Sue Ann Pentecost, +1-919-456-5890, sueann.pentecost@rtp.ppdi.com, or Analysts and Investors, Craig Eastwood, +1-910-558-7517, craig.eastwood@wilm.ppdi.com, both of PPD, Inc.
Comments